Search results for "Leucemia promielocítica aguda"

showing 2 items of 2 documents

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

Características y resultado a largo plazo de pacientes mayores con leucemia promielocítica aguda tratados con esquemas terapéuticos basados en ATRA m…

2015

La leucemia promielocítica aguda (LPA) es un subtipo de leucemia mieloide aguda que se diferencia por una morfología característica y la presencia de la t(15;17) y su correspondiente reordenamiento molecular PML/RARa. Clínicamente, no es infrecuente que se presente con coagulopatía, pudiendo ser la responsable de la muerte del paciente incluso antes del diagnóstico. No obstante, su buena respuesta al tratamiento con ácido holo-trans retinoico (ATRA) se ha traducido en una importante mejoría de la tasa de remisión completa y de la supervivencia a partir de su introducción, suponiendo una de sus características más satisfactorias. Las actuales recomendaciones para el tratamiento de los pacien…

mayoresantraciclinasUNESCO::CIENCIAS MÉDICASleucemia promielocítica aguda:CIENCIAS MÉDICAS [UNESCO]
researchProduct